Many Faces of Adrenal Lesions in a Large Patient Cohort: What Has Changed Over the Last Two Decades?

Abstract

Objective To review the presentation characteristics, clinical and hormonal evaluations, and histopathological results of patients with adrenal lesions over a 21-year period and evaluate the changes across the two decades.

Methods This single-center, retrospective study included 1003 patients with adrenal lesions who presented to our department between 2000 and 2021. Clinical, metabolic, hormonal, radiological, and pathological data of the patients were collected.

Results Forty-seven percent of the lesions were non-functioning adrenal adenomas. Possible autonomous and autonomous cortisol secretion were detected in 22.2% of the patients. The percentages of the patients diagnosed with pheochromocytoma, primary hyperaldosteronism, adrenal Cushing syndrome, adrenocortical carcinoma, and adrenal metastasis were 7.4%, 4.8%, 4.7%, 0.9%, and 5.6%, respectively. Adrenalectomy was performed in 31.3% of the patients. Functional adrenal lesions were the leading cause of surgery (46.5%), followed by large size and/or suspicious imaging features (38.6%). Among the patients referred to surgery due to large size (≥6 cm), the diagnosis in 19% was metastasis, and in 12.1%, it was primary adrenocortical carcinoma. In patients with adrenal lesions with a size of 4–6 cm and suspicious imaging properties, the rates of metastasis and primary adrenocortical carcinoma were 44.4% and 4.8%, respectively. From the first to the second decade, major differences in presentation characteristics were increased detection of bilateral lesions and increased prevalence of possible autonomous and autonomous cortisol secretion.

Conclusions Adrenal lesions are common in the adult population, and while it is important to avoid overtreatment, hormone secretion, and malignancy should not be overlooked.

Key words

adrenal incidentaloma - adrenal lesions - adrenocortical carcinoma - subclinical Cushing syndrome - autonomous cortisol secretion

Publikationsverlauf

Eingereicht: 28. Oktober 2022
Eingereicht: 28. Januar 2023

Angenommen: 07. Februar 2023

Accepted Manuscript online:
14. Februar 2023

Artikel online veröffentlicht:
03. April 2023

• References

• 1 Fassnacht M, Arlt W, Bancos I. et al. Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol 2016; 175: G1-G34
• 2 Barzon L, Sonino N, Fallo F. et al. Prevalence and natural history of adrenal incidentalomas. Eur J Endocrinol 2003; 149: 273-285
• 3 Kloos RT, Gross MD, Francis IR. et al. Incidentally discovered adrenal masses. Endocr Rev 1995; 16: 460-484
• 4 Song JH, Chaudhry FS, Mayo-Smith WW. The incidental adrenal mass on CT: Prevalence of adrenal disease in 1,049 consecutive adrenal masses in patients with no known malignancy. AJR Am J Roentgenol 2008; 190: 1163-1168
• 5 Comlekci A, Yener S, Ertilav S. et al. Adrenal incidentaloma, clinical, metabolic, follow-up aspects: Single centre experience. Endocrine 2010; 37: 40-46
• 6 Mantero F, Terzolo M, Arnaldi G. et al. A survey on adrenal incidentaloma in Italy. Study Group on Adrenal Tumors of the Italian Society of Endocrinology. J Clin Endocrinol Metab 2000; 85: 637-644
• 7 Muth A, Hammarstedt L, Hellstrom M. et al. Cohort study of patients with adrenal lesions discovered incidentally. Br J Surg 2011; 98: 1383-1391
• 8 Pasternak JD, Seib CD, Seiser N. et al. Differences between bilateral adrenal incidentalomas and unilateral lesions. JAMA Surg 2015; 150: 974-978
• 9 Satman I, Omer B, Tutuncu Y. et al. Twelve-year trends in the prevalence and risk factors of diabetes and prediabetes in Turkish adults. Eur J Epidemiol 2013; 28: 169-180
• 10 Mendola ND, Chen TC, Gu Q. et al. Prevalence of total, diagnosed, and undiagnosed diabetes among adults: United States, 2013-2016. NCHS Data Brief 2018; 1-8
• 11 Reimondo G, Castellano E, Grosso M. et al. Adrenal incidentalomas are tied to increased risk of diabetes: Findings from a prospective study. J Clin Endocrinol Metab 2020; 105
• 12 Yener S, Comlekci A, Yuksel F. et al. Traditional and novel cardiovascular risk factors in non-functioning adrenal adenomas. Eur J Intern Med 2012; 23: 83-87
• 13 Morelli V, Reimondo G, Giordano R. et al. Long-term follow-up in adrenal incidentalomas: An Italian multicenter study. J Clin Endocrinol Metab 2014; 99: 827-834
• 14 Deutschbein T, Reimondo G, Di Dalmazi G. et al. Age-dependent and sex-dependent disparity in mortality in patients with adrenal incidentalomas and autonomous cortisol secretion: An international, retrospective, cohort study. Lancet Diabetes Endocrinol 2022; 10: 499-508
• 15 Di Dalmazi G, Vicennati V, Rinaldi E. et al. Progressively increased patterns of subclinical cortisol hypersecretion in adrenal incidentalomas differently predict major metabolic and cardiovascular outcomes: A large cross-sectional study. Eur J Endocrinol 2012; 166: 669-677
• 16 Chiodini I. Clinical review: Diagnosis and treatment of subclinical hypercortisolism. J Clin Endocrinol Metab 2011; 96: 1223-1236
• 17 Yener S, Ertilav S, Secil M. et al. Prospective evaluation of tumor size and hormonal status in adrenal incidentalomas. J Endocrinol Invest 2010; 33: 32-36
• 18 Mosso L, Carvajal C, Gonzalez A. et al. Primary aldosteronism and hypertensive disease. Hypertension 2003; 42: 161-165
• 19 Stavropoulos K, Imprialos KP, Katsiki N. et al. Primary aldosteronism in patients with adrenal incidentaloma: Is screening appropriate for everyone?. J Clin Hypertens (Greenwich) 2018; 20: 942-948